[extropy-chat] Lifeline Nutraceuticals and Ceremedix news

[Giu1i0 Pri5c0]

>From the Lifeline Nutraceuticals and Ceremedix websites and mailing lists:
Protandim has now been covered by over 120 media sources stretching all
across the globe. Feature articles in major newspapers, as well as coverage
by an NBC news affiliate and international radio broadcasts.
Lifeline Nutraceuticals (Lifeline) is currently looking to close out its
fundraising that is earmarked for FDA approval processes and product
commercialization. Closing has been delayed due to contractual obligations,
but we hope to break escrow by mid February. Internal and independent
product tests have been conducted, but some of these studies will be
repeated for the FDA as soon as the funding is finalized. Final human trials
will also begin at that time.
Lifeline is a privately held Denver-based nutraceutical licensing and
marketing company. Lifeline has a unique anti-aging nutraceutical, protandim
(TM), that acts by mobilizing the body's own defense and repair mechanisms,
resulting in the rescue of tissues and organs of the body that would
otherwise be irrevocably damaged by the effects of "oxidative stress" caused
by aging and numerous diseases.
Quite a few inquiries have revolved around the publication date of studies
that have already been completed. Lifeline and its affiliate pharmaceutical
company, CereMedix, have intentionally chosen to not publish studies at this
time.
CereMedix, Inc., is a privately held Massachusetts-based drug discovery and
development company. CereMedix has a unique portfolio of peptide-based
product candidates with the unique action of activating certain genes
present in cells of the human body that act as the bodys own defend and
repair mechanisms. The switching on of these genes results in the rescue of
tissues and organs of the body that would otherwise be irrevocably damaged
by the effects of oxidative stress resulting from aging and multiple
diseases. The company is targeting its therapeutic products at multi-billion
dollar markets with no viable existing therapeutics.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.extropy.org/pipermail/extropy-chat/attachments/20040107/a11ba1e9/attachment.html>